GeoVax Labs Inc (GOVX) Live Share Price, Invest From India

GeoVax Labs Inc Stock Performance

as on June 5, 2026 at 6:59 am IST

Day's Low
Day's High
$1.67
Day's Price Range
$2.15
$1.82
8.24%
Downside
18.13%
Upside
52 Week's Low
52 Week's High
$0.96
52-Week Price Range
$34.75
$1.82
47.08%
Downside
1809.34%
Upside

GeoVax Labs Inc share price movements today

Previous Close: $2.03
Open: $1.96
Volume: 2.9M
Day's Low - High: $1.67 - $2.15
52 Week Low - High: $0.96 - $34.75

GeoVax Labs Inc Historical Returns

1 Month Return: + 59.84 %
3 Month Return: + 18.71 %
1 Year Return: -92.75 %
3 Year Return: -99.13 %
5 Year Return: -99.89 %

GeoVax Labs Inc Stock Fundamentals & Key Indicators

Check GeoVax Labs Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$10.6M

EPS (TTM)

-8.695

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

PEG Ratio

EBITDA

-21.4M

Revenue (TTM)

852.3K

Profit Margin

0.00%

Return On Equity TTM

-509.28%

GeoVax Labs Inc vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of GeoVax Labs Inc with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %	Dividend Yield %
GeoVax Labs Inc	BUY	$10.6M	-99.89%	NA	0.00%	NA
Revolution Medicines Inc	BUY	$32.2B	411.61%	NA	0.00%	NA
Alnylam Pharmaceuticals Inc	BUY	$39.1B	100.95%	73.51	12.55%	NA
Vertex Pharmaceuticals Inc	BUY	$108.7B	104.04%	25.45	35.51%	NA
Regeneron Pharmaceuticals Inc	BUY	$64.9B	20.91%	15.11	29.65%	0.59%

Stock Returns calculator for GeoVax Labs Inc Stock including INR - Dollar returns

The GeoVax Labs Inc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

GeoVax Labs Inc investment value today

Current value as on today

₹7,249

Returns

-₹92,751

(-92.75%)

Returns from GeoVax Labs Inc Stock

-₹93,500 (-93.5%)

Dollar Impact

₹749 (+0.75%)

Analyst Recommendation on GeoVax Labs Inc Stock

Based on 9 analysts

BUY

88.89%

Buy

11.11%

Hold

0.00%

Sell

Based on 9 analysts, 88.89% of analysts recommend a 'BUY' rating for GeoVax Labs Inc. Average target price of $10

GeoVax Labs Inc Share Price Target

Get share price movements and forecasts by analysts on GeoVax Labs Inc.

What analysts predicted

81.8%UPSIDE

Target Price

$10

Current Price

$1.82

Analyzed by

9 Analysts

Target

$10.00

GeoVax Labs Inc target price $10, a slight upside of 81.8% compared to current price of $1.82. According to 9 analysts rating.

Indian Investors' Interest in GeoVax Labs Inc Stock

Investment in GeoVax Labs Inc Shares on INDmoney has grown by 1508.69% in the last 30 days, indicating increased investment activity.

Time period: May 6, 2026 to June 5, 2026

Change:1508.69% versus previous 30 day period

Search interest for GeoVax Labs Inc Stock has increased by 951% in the last 30 days, reflecting an upward trend in search activity.

Time period: May 6, 2026 to June 5, 2026

Change:951% versus previous 30 day period

GeoVax Labs Inc Quarterly Profit & Loss

All numbers in Millions USD

	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Total Revenue	0	-	0	2	0	1	0	-	-	-
Gross Profit	0	0	0	2	0	1	0	0	-	0
Operating Income	-7	-5	-5	-5	-8	-5	-5	-6	-4	-5
EBITDA	-7	-5	-5	-5	-8	-5	-5	-6	-	-5
Interest Expense	0	-	0	0	-	-	-	-	-	-
Depreciation	0	0	0	0	0	0	0	0	0	0
Income Before Tax	-7	-5	-5	-5	-8	-5	-5	-6	-4	-5
Income Tax Expense	0	0	0	-	-	-	-	-	-	-
Net Income	-7	-5	-5	-5	-8	-5	-5	-6	-4	-5
Net Profit Margin	-7306.57%	0.00%	-1684.21%	-208.48%	-955.87%	-327.31%	-630.05%	0.00%	0.00%	0.00%

GeoVax Labs Inc Annual Profit & Loss

All numbers in Millions USD

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Revenue	0	1	0	1	1	0	0	-	3	2
Gross Profit	-1	0	0	1	1	0	0	-20	3	2
Operating Income	-3	-2	-2	-2	-2	-18	-14	-26	-25	-21
EBITDA	-3	-2	-2	-2	-2	-18	-13	-26	-24	-21
Interest Expense	-	-	0	0	0	0	0	-	0	-
Depreciation	-	0	0	0	0	0	0	0	0	0
Income Before Tax	-3	-2	-2	-2	-2	-18	-14	-25	-24	-21
Income Tax Expense	-	-	0	0	0	0	0	0	-	-
Net Income	-3	-2	-2	-2	-2	-18	-14	-25	-24	-21
Net Profit Margin	-394.70%	-201.82%	-265.84%	-201.60%	-161.18%	-4813.37%	-17301.93%	0.00%	-631.98%	-862.34%

GeoVax Labs Inc Quarterly Cash Flow

All numbers in Millions USD

	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Net Income	-5	-5	-5	-8	-5	-5	-6	-4	-5
Operating Cash Flow	-5	-1	-9	-7	-5	-4	-6	-4	-3
Investing Cash Flow	-	-	0	-	0	0	0	-	-27,612
Financing Cash Flow	-	2	16	4	7	0	8	3	1
Change in Cash	-5	0	7	-3	1	-4	1	-1	-1

GeoVax Labs Inc Annual Cash Flow

All numbers in Millions USD

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Net Income	-2	-2	-2	-2	-18	-14	-25	-24	-21
Operating Cash Flow	-1	-1	-1	-2	-11	-19	-25	-24	-21
Investing Cash Flow	0	0	0	0	0	0	0	0	0
Financing Cash Flow	1	1	1	12	12	35	4	23	19
Change in Cash	0	0	0	9	1	16	-21	0	-2

Global Institutional Holdings in GeoVax Labs Inc

Funds	Holdings
UBS Group AG	0.08%
Morgan Stanley - Brokerage Accounts	0%
Bank of America Corp	0%
Tower Research Capital LLC	0.12%
Advisor Group Holdings, Inc.	0%

See all

Insights on GeoVax Labs Inc

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

NO EFFECT
Against Peers
In the last 1 year, Revolution Medicines, Inc. Common Stock has given 286.3% return, outperforming this stock by 379.1%
NO EFFECT
Against Peers
In the last 3 years, Revolution Medicines, Inc. Common Stock has given 510.1% return, outperforming this stock by 609.2%
NEGATIVE IMPACT
Price Dip
In the last 7 days, GOVX stock has moved down by -15.4%

About GeoVax Labs Inc

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States. It develops GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, the company offers GEO-MVA-MUC1, a vaccine candidate, which is in preclinical trial for the treatment of solid tumor cancers; GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-EMO1-Z, which is in preclinical trial for the treatment of Ebola Zaire; GEO-EMO1-S, which is in preclinical trial for the treatment of Ebola Sudan; GEO-MM01 treatment for marburg; and GEO-MVA for the treatment of Mpox and small pox. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; and the U.S. Department of Defense. GeoVax Labs, Inc. was incorporated in 1988 and is based in Smyrna, Georgia.

Organisation	GeoVax Labs Inc
Headquarters	1955 Lake Park Drive, Smyrna, GA, United States, 30080
Industry	Biotechnology
CEO	Mr. David Alan Dodd
E-voting on shares	Click here to vote

Key Management of GeoVax Labs Inc

Name	Title
Dr. Mark J. Newman Ph.D.	Chief Scientific Officer
Dr. Kelly T. McKee Jr., M.D., M.P.H.	Chief Medical Officer
Dr. Harriet Latham Robinson Ph.D.	Founder, Chief Scientific Officer Emeritus & Member of Scientific Advisory Board
Mr. Thomas O'Brien	Vice President of Quality Systems & Compliance
Mr. Jeffrey Welch	Head of Process Development & Manufacturing Operations
Dr. John W. Sharkey Ph.D.	Vice President of Business Development
Mr. David Alan Dodd	Chairman, President & CEO

FAQs

What is GeoVax Labs Inc share price today?

GeoVax Labs Inc share price today is $1.82 as on June 5, 2026 at 1:29 am IST at the close of the market. GeoVax Labs Inc share today touched a day high of $2.15 and a low of $1.67.

What is the 52 week high and 52 week low for GeoVax Labs Inc share?

GeoVax Labs Inc share touched a 52 week high of $34.75 on June 16, 2025 and a 52 week low of $0.96 on April 29, 2026. GeoVax Labs Inc stock price today i.e. June 5, 2026 at 1:29 am IST is closed at $1.82,which is 94.76% down from its 52 week high and 88.97% up from its 52 week low.

What is GeoVax Labs Inc's market capitalisation today?

GeoVax Labs Inc market capitalisation is $0.00T as on June 5, 2026 at 1:29 am IST.

How to invest in GeoVax Labs Inc Stock (GOVX) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for GeoVax Labs Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in GeoVax Labs Inc Shares that will get you 0.8242 shares as per GeoVax Labs Inc share price of $1.82 per share as on June 5, 2026 at 1:29 am IST.

What is the minimum amount required to buy GeoVax Labs Inc Stock (GOVX) from India?

Indian investors can start investing in GeoVax Labs Inc (GOVX) shares with as little as ₹95.775 or $1 (as of June 5, 2026 at 1:59 am IST) using the INDmoney app.
For example: If you want to invest $10 or ₹957.75 in GeoVax Labs Inc stock (as per the Rupee-Dollar exchange rate as on June 5, 2026 at 1:59 am IST). Based on GeoVax Labs Inc share’s latest price of $1.82 as on June 5, 2026 at 1:29 am IST, you will get 5.4945 shares of GeoVax Labs Inc. Learn more about fractional shares .

What are the returns that GeoVax Labs Inc has given to Indian investors in the last 5 years?

GeoVax Labs Inc stock has given -99.89% share price returns and 30.36% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?